Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Overall survival · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of acute GVHD grade II to IV · people receiving allogeneic hematopoietic stem cell transplantation
It is very uncertain whether mycophenolate mofetil changes prevention of acute GVHD grade II to IV compared with methotrexate (very low certainty).
1 finding from 1 review
Relapse · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).
1 finding from 1 review
Nonrelapse mortality · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of chronic GVHD · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in prevention of chronic GVHD compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of severe mucositis · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of severe mucositis compared with methotrexate (low certainty).
1 finding from 1 review
Use of total parenteral nutrition · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower use of total parenteral nutrition compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of narcotic use for pain control · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil may leads to lower incidence of narcotic use for pain control compared with methotrexate (low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
Summary of findings: Ursodeoxycholic acid may leads to lower incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes incidence of hepatic veno‐occlusive disease ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Overall survival · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · People undergoing stem cell transplant with malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · People undergoing stem cell transplant with malignant diseases
It is very uncertain whether summary of findings: Low molecular weight heparin changes frequency of adverse events ( compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Incidence of hepatic veno‐occlusive disease ( · Children undergoing stem cell transplant with malignant and non‐malignant diseases and risk factors for hepatic veno‐occlusive disease
Summary of findings: Defibrotide showed no clear difference in incidence of hepatic veno‐occlusive disease ( compared with no treatment (low certainty).
1 finding from 1 review